PharVision Advisers’s Saul Centers BFS Stock Holding History

PharVision Advisers’s Portfolio BFS Stock Details BFS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,862	Closed	-$248K	–	156
2025 Q4	$248K	Buy	+7,862	New	+$242K	0.13%	396

Other funds holding BFS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PharVision Advisers's BFS Position: Q1 2026 in Review

PharVision Advisers sold out of Saul Centers (BFS) in Q1 2026, closing a stake of 7,862 shares — an estimated $248K sold.

PharVision Advisers first reported a position in BFS in Q4 2025 and held it in 1 quarter. The position peaked at $248K in Q4 2025. 182 funds tracked by Wall St. Rank hold BFS as of Q1 2026.

PharVision Advisers reported no remaining Saul Centers position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 7,862 Saul Centers shares in Q1 2026, an estimated $248K.
PharVision Advisers first reported a position in Saul Centers in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Saul Centers position peaked at $248K in Q4 2025.
182 funds tracked by Wall St. Rank held Saul Centers as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.